Compare Recursion Pharmaceuticals Inc (RXRX) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Royal Bank of Canada — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B), while Royal Bank of Canada trades at $210.44 (market cap $292.92B). The key difference: Royal Bank of Canada is far larger — about 164.6× Recursion Pharmaceuticals Inc's market cap, and Royal Bank of Canada pays a 2.36% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | RY | |
|---|---|---|
Market Cap | $1.78B | $292.92B |
Sector | Health | Financials |
52-Week High | $6.79 | $217.87 |
52-Week Low | $2.84 | $133.43 |
Enterprise Value | $1.30B | — |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Royal Bank of Canada (RY) trades at $211.08, down 0.17% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.84 exceeding expectations. Revenue grew to $66.53B in 2025, and net income margin improved to 31.85%. Analyst consensus is mixed, with 43% buy ratings, while recent news highlights insider selling and institutional adjustments to holdings.
RY presents a solid investment case with robust profitability and consistent earnings outperformance, though valuation ratios like P/E of 19.23 and P/B of 3.17 suggest a premium. Risks include high debt levels and macroeconomic sensitivity, but the bullish technical trend and dividend yield support a cautiously optimistic outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
